BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23587125)

  • 1. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.
    Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G
    Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
    Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
    Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
    Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
    Fervenza FC; Abraham RS; Erickson SB; Irazabal MV; Eirin A; Specks U; Nachman PH; Bergstralh EJ; Leung N; Cosio FG; Hogan MC; Dillon JJ; Hickson LJ; Li X; Cattran DC;
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2188-98. PubMed ID: 20705965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
    Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].
    Wéclawiak H; Ribes D; Modesto A; Kamar N; Durand D; Rostaing L
    Nephrol Ther; 2007 Apr; 3(2):65-8. PubMed ID: 17452303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
    van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
    J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
    Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
    J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
    Irazabal MV; Eirin A; Lieske J; Beck LH; Sethi S; Borland TM; Dillon JJ; Nachman PH; Nasr SH; Cornell LD; Leung N; Cattran DC; Fervenza FC
    Nephrol Dial Transplant; 2013 Jan; 28(1):137-46. PubMed ID: 22987142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Membranous nephropathy secondary to rheumatoid arthritis occurring during anti-TNFalpha therapy and responsive to second-line treatment with rituximab].
    Giordano A; Cencioni L; Salvo DP; Berrettini M
    G Ital Nefrol; 2011; 28(2):214-8. PubMed ID: 21488037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
    De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
    Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab treatment of idiopathic membranous nephropathy.
    Fervenza FC; Cosio FG; Erickson SB; Specks U; Herzenberg AM; Dillon JJ; Leung N; Cohen IM; Wochos DN; Bergstralh E; Hladunewich M; Cattran DC
    Kidney Int; 2008 Jan; 73(1):117-25. PubMed ID: 17943078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine treatment in idiopathic membranous nephropathy nephrotic syndrome in adults: a retrospective study spanning 15 years.
    Tao JL; Liu LL; Wen YB; Gao RT; Li H; Li MX; Li XM; Li XW
    Chin Med J (Engl); 2011 Nov; 124(21):3490-4. PubMed ID: 22340164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in idiopathic membranous nephropathy.
    Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
    J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
    Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
    Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.